Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2011/584238 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555950427340800 |
|---|---|
| author | J. Fernando Arevalo Juan G. Sanchez Andres F. Lasave Lihteh Wu Mauricio Maia Sergio Bonafonte Miguel Brito Arturo A. Alezzandrini Natalia Restrepo Maria H. Berrocal Mario Saravia Michel Eid Farah Jans Fromow-Guerra Virgilio Morales-Canton |
| author_facet | J. Fernando Arevalo Juan G. Sanchez Andres F. Lasave Lihteh Wu Mauricio Maia Sergio Bonafonte Miguel Brito Arturo A. Alezzandrini Natalia Restrepo Maria H. Berrocal Mario Saravia Michel Eid Farah Jans Fromow-Guerra Virgilio Morales-Canton |
| author_sort | J. Fernando Arevalo |
| collection | DOAJ |
| description | This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy. |
| format | Article |
| id | doaj-art-bd5b5b96a1914e8886de786f5e71ef4d |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-bd5b5b96a1914e8886de786f5e71ef4d2025-02-03T05:46:46ZengWileyJournal of Ophthalmology2090-004X2090-00582011-01-01201110.1155/2011/584238584238Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF LectureJ. Fernando Arevalo0Juan G. Sanchez1Andres F. Lasave2Lihteh Wu3Mauricio Maia4Sergio Bonafonte5Miguel Brito6Arturo A. Alezzandrini7Natalia Restrepo8Maria H. Berrocal9Mario Saravia10Michel Eid Farah11Jans Fromow-Guerra12Virgilio Morales-Canton13Retina and Vitreous Service, Caracas Clinical Opthalmology Center, Caracas 1010, VenezuelaRetina and Vitreous Service, Instituto Nacional de Investigación en Oftalmologica (INIO), Medellín, ColombiaRetina and Vitreous Service, Caracas Clinical Opthalmology Center, Caracas 1010, VenezuelaRetina and Vitreous Service, Instituto de Cirugia Ocular, San José, Costa RicaDepartamento de Oftalmologica, Instituto da Visão, Universidad Federal de São Paulo, 04021-001 São Paulo, SP, BrazilRetina and Vitreous Service, Centro de Oftalmología Bonafonte, Barcelona, SpainRetina and Vitreous Service, Instituto Docente de Especialidades Oftalmológicas (IDEO), Maracaibo, VenezuelaOFTALMOS, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, ArgentinaRetina and Vitreous Service, Instituto Nacional de Investigación en Oftalmologica (INIO), Medellín, ColombiaDepartment of Ophthalmology, University of Puerto Rico, San Juan, Puerto RicoDepartment of Ophthalmology, Hospital Universitario Austral, Buenos Aires, ArgentinaDepartamento de Oftalmologica, Instituto da Visão, Universidad Federal de São Paulo, 04021-001 São Paulo, SP, BrazilHospital Dr. Luis Sanchez Bulnes, Asociación Para Evitar la Ceguera en Mexico 04030, Mexico City, MexicoHospital Dr. Luis Sanchez Bulnes, Asociación Para Evitar la Ceguera en Mexico 04030, Mexico City, MexicoThis paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.http://dx.doi.org/10.1155/2011/584238 |
| spellingShingle | J. Fernando Arevalo Juan G. Sanchez Andres F. Lasave Lihteh Wu Mauricio Maia Sergio Bonafonte Miguel Brito Arturo A. Alezzandrini Natalia Restrepo Maria H. Berrocal Mario Saravia Michel Eid Farah Jans Fromow-Guerra Virgilio Morales-Canton Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture Journal of Ophthalmology |
| title | Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture |
| title_full | Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture |
| title_fullStr | Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture |
| title_full_unstemmed | Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture |
| title_short | Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture |
| title_sort | intravitreal bevacizumab avastin for diabetic retinopathy the 2010 gladaof lecture |
| url | http://dx.doi.org/10.1155/2011/584238 |
| work_keys_str_mv | AT jfernandoarevalo intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT juangsanchez intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT andresflasave intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT lihtehwu intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT mauriciomaia intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT sergiobonafonte intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT miguelbrito intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT arturoaalezzandrini intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT nataliarestrepo intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT mariahberrocal intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT mariosaravia intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT micheleidfarah intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT jansfromowguerra intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture AT virgiliomoralescanton intravitrealbevacizumabavastinfordiabeticretinopathythe2010gladaoflecture |